Trials / Completed
CompletedNCT00168012
Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)
An Open Study to Evaluate the Safety and Efficacy of IVIG-F10 in Patients With Primary Immunodeficiency Diseases (PID)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 42 (planned)
- Sponsor
- CSL Behring · Industry
- Sex
- All
- Age
- 3 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate the effect of IVIG-F10 on the prevention of serious bacterial infections in patients with primary immunodeficiency. As secondary endpoints the rate of overall infections, the tolerability and safety of IVIG-F10 are studied.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Immunoglobulins Intravenous (Human) |
Timeline
- Start date
- 2004-09-01
- Completion
- 2005-09-01
- First posted
- 2005-09-14
- Last updated
- 2011-02-11
Source: ClinicalTrials.gov record NCT00168012. Inclusion in this directory is not an endorsement.